| Autor: |
Callisia N. Clarke, Paul Cockrum, Thomas J.R. Beveridge, Michelle Jerry, Donna McMorrow, Anh Thu Tran, Alexandria T. Phan |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Journal of Health Economics and Outcomes Research, Vol 10, Iss 2 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2327-2236 |
| DOI: |
10.36469/001c.89300 |
| Popis: |
**Background:** Long-acting somatostatin analog therapy (LA-SSA) is recommended as first-line therapy for treatment of unresectable or metastatic neuroendocrine tumors (NETs). Understanding treatment sequencing and dosing patterns of LA-SSA is essential for clinical decision-making to provide value-based management of NETs. **Objective:** To describe treatment patterns of LA-SSA among patients with NETs and subgroups with carcinoid syndrome (CS) in the United States. **Methods:** This retrospective study utilized claims data from MarketScan® databases to identify patients with NETs and newly treated with LA-SSA between January 1, 2015, and October 31, 2020. Patients were stratified by index LA-SSA (lanreotide and octreotide long-acting release \[LAR\]). Reported 28-day doses were based on claim fields for days’ supply/drug quantity or units of service. Dose escalation was defined as increases in quantity or frequency. Continuous variables, categorical variables, and Kaplan-Meier estimated treatment durations were compared using _t_-tests, chi-square/Fisher’s tests, and log-rank tests, respectively. **Results:** The study included 241 lanreotide and 521 octreotide LAR patients. Compared with octreotide LAR patients, treatment duration was longer for lanreotide patients (median, 41.3 vs 26.8 months; log-rank _p_=.004). Fewer lanreotide patients received rescue treatment with short-acting octreotide (7.9% vs 14.4%; _p_=.011), and a first (6.2% vs 27.3%) and second dose escalation (0.8% vs 5.2%; both _p_ |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
